908 related articles for article (PubMed ID: 21131036)
41. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
[TBL] [Abstract][Full Text] [Related]
42. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
Schaich M; Parmentier S; Kramer M; Illmer T; Stölzel F; Röllig C; Thiede C; Hänel M; Schäfer-Eckart K; Aulitzky W; Einsele H; Ho AD; Serve H; Berdel WE; Mayer J; Schmitz N; Krause SW; Neubauer A; Baldus CD; Schetelig J; Bornhäuser M; Ehninger G
J Clin Oncol; 2013 Jun; 31(17):2094-102. PubMed ID: 23630210
[TBL] [Abstract][Full Text] [Related]
43. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
44. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.
Burnett AK; Hills RK; Milligan DW; Goldstone AH; Prentice AG; McMullin MF; Duncombe A; Gibson B; Wheatley K
J Clin Oncol; 2010 Feb; 28(4):586-95. PubMed ID: 20038732
[TBL] [Abstract][Full Text] [Related]
45. Therapy of acute myelogenous leukemia: results of combination chemotherapy with cytarabine, daunorubicin and 6-mercaptopurine.
Ko WS; Chen LM; Hwang SH; Chao TY; Wang CC; Kao WY; Lee WC; Hwang WS
Zhonghua Yi Xue Za Zhi (Taipei); 1991 Sep; 48(3):185-9. PubMed ID: 1657335
[TBL] [Abstract][Full Text] [Related]
46. Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.
Kim HP; Bernard L; Berkowitz J; Nitta J; Hogge DE
Cytometry B Clin Cytom; 2012 Sep; 82(5):283-94. PubMed ID: 22508650
[TBL] [Abstract][Full Text] [Related]
47. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial.
Wang H; Mao L; Yang M; Qian P; Lu H; Tong H; Xie W; Zhou D; Huang X; Wang Y; Xu G; Lu Y; Wei J; Mai W; Ye X; Meng H; Shen Y; Huang J; Yu W; Sun J; Sheng J; Yan X; Jin J; Zhu HH
Lancet Haematol; 2022 Jun; 9(6):e415-e424. PubMed ID: 35512726
[TBL] [Abstract][Full Text] [Related]
48. Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
Nørgaard JM; Langkjer ST; Palshof T; Pedersen B; Hokland P
Eur J Haematol; 2001 Mar; 66(3):160-7. PubMed ID: 11350484
[TBL] [Abstract][Full Text] [Related]
49. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia.
Wahlin A; Hörnsten P; Hedenus M; Malm C
Cancer Chemother Pharmacol; 1991; 28(6):480-3. PubMed ID: 1934252
[TBL] [Abstract][Full Text] [Related]
50. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia.
Schiller G; Gajewski J; Nimer S; Territo M; Ho W; Lee M; Champlin R
Br J Haematol; 1992 Jun; 81(2):170-7. PubMed ID: 1643014
[TBL] [Abstract][Full Text] [Related]
51. Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine.
Grigg AP; Reynolds J; McQuillan A; Juneja SK; Di Iulio J; Hui C; Smith C; Kimber R; Bradstock KF;
Leuk Lymphoma; 2005 Mar; 46(3):367-75. PubMed ID: 15621826
[TBL] [Abstract][Full Text] [Related]
52. The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia.
Tricot G; Boogaerts MA; Vlietinck R; Emonds MP; Verwilghen RL
Br J Haematol; 1987 May; 66(1):37-44. PubMed ID: 3474014
[TBL] [Abstract][Full Text] [Related]
53. Conventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta-analysis of 7258 patients.
Sekine L; Morais VD; Lima KM; Onsten TG; Ziegelmann PK; Ribeiro RA
Hematol Oncol; 2015 Dec; 33(4):212-9. PubMed ID: 25363800
[TBL] [Abstract][Full Text] [Related]
54. Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia.
Matthews JP; Bishop JF; Young GA; Juneja SK; Lowenthal RM; Garson OM; Cobcroft RG; Dodds AJ; Enno A; Gillett EA; Hermann RP; Joshua DE; Ma DD; Szer J; Taylor KM; Wolf M; Bradstock KF;
Br J Haematol; 2001 Jun; 113(3):727-36. PubMed ID: 11380464
[TBL] [Abstract][Full Text] [Related]
55. [Chemotherapy of adult ANLL].
Kyo T; Maehama S
Rinsho Ketsueki; 1989 Aug; 30(8):1157-62. PubMed ID: 2601024
[TBL] [Abstract][Full Text] [Related]
56. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
Hills RK; Castaigne S; Appelbaum FR; Delaunay J; Petersdorf S; Othus M; Estey EH; Dombret H; Chevret S; Ifrah N; Cahn JY; Récher C; Chilton L; Moorman AV; Burnett AK
Lancet Oncol; 2014 Aug; 15(9):986-96. PubMed ID: 25008258
[TBL] [Abstract][Full Text] [Related]
57. Treatment of older patients with acute myeloid leukaemia.
Ferrara F
Lancet; 2010 Dec; 376(9757):1967-8. PubMed ID: 21131041
[No Abstract] [Full Text] [Related]
58. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults.
Phillips GL; Reece DE; Shepherd JD; Barnett MJ; Brown RA; Frei-Lahr DA; Klingemann HG; Bolwell BJ; Spinelli JJ; Herzig RH
Blood; 1991 Apr; 77(7):1429-35. PubMed ID: 2009367
[TBL] [Abstract][Full Text] [Related]
59. Long-term follow-up of patients >or=60 yr old with acute myeloid leukaemia treated with intensive chemotherapy.
Oberg G; Killander A; Björeman M; Gahrton G; Grimfors G; Gruber A; Hast R; Lerner R; Liliemark J; Mattson S; Paul C; Simonsson B; Stalfelt AM; Stenke L; Tidefelt U; Udén AM; Björkholm M;
Eur J Haematol; 2002 Jun; 68(6):376-81. PubMed ID: 12225396
[TBL] [Abstract][Full Text] [Related]
60. Chemotherapy of adult acute myeloid leukaemia.
Suri R; Kueh YK; Han P; Tan YO
Ann Acad Med Singap; 1990 Mar; 19(2):175-7. PubMed ID: 2346291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
